Johnson & Johnson (JNJ) CEO Joaquin Duato on Q4 2021 Results - Earnings Call Transcript

Jan. 25, 2022 12:44 PM ETJohnson & Johnson (JNJ) Stock
SA Transcripts profile picture
SA Transcripts
150.28K Followers

Q4: 2022-01-25 Earnings Summary

10-K
EPS of $2.13 beats by $0.01 | Revenue of $24.80B (10.36% Y/Y) misses by $485.39M

Johnson & Johnson (NYSE:JNJ) Q4 2021 Earnings Conference Call January 25, 2022 8:30 AM ET

Company Participants

Jessica Moore - Vice President of Investor Relations
Joseph Wolk - Executive Vice President, Chief Financial Officer
Joaquin Duato - Chief Executive Officer

Conference Call Participants

Louise Chen - Cantor Fitzgerald
Larry Biegelsen - Wells Fargo
Joshua Jennings - Cowen and Company
Christopher Schott - JPMorgan
Joanne Wuensch - Citigroup
Matthew Miksic - Credit Suisse
Danielle Antalffy - SVB Leerink
Chris Shibutani - Goldman Sachs

Operator

Good morning. Welcome to Johnson & Johnson's Fourth Quarter 2021 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions].

I would now like to turn the conference call over to Johnson & Johnson. You may begin.

Jessica Moore

Good morning. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the fourth quarter and full year of 2021 and our financial outlook for 2022. Joining me on today's call are Joaquin Duato, Chief Executive Officer; and Joe Wolk, Executive Vice President, Chief Financial Officer.

A few logistics before we get into the details.

This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com, where you can also find additional materials, including today's presentation and associated schedules. Please note that today's presentation includes forward-looking statements regarding, among other things, our future operating and financial performance and the anticipated separation of the company's Consumer Health business. We encourage you to review the cautionary statement included in today's presentation, which identifies certain risks and factors that may cause the company's actual results to differ materially from those projected. In particular, there

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on JNJ